Summary

The Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Subjects With Type 2 Diabetes Mellitus study [ENDURE; NCT00856284] showed that there were greater reductions in the primary endpoint of least square mean change from baseline in HbA1C at 104 weeks with two doses of the DPP-4 inhibitor alogliptin compared with the sulfonylurea glipizide.